{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4",
      "authorship_tag": "ABX9TyOGIJXl30V0t7+jpEDl9yT/",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/IyadSultan/Basic_Flask_site/blob/master/educational/Named_Entity_Extraction/Named_Entity_Extraction_spaCy.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **Extract any named entities from PDF using custom Spacy pipeline**\n",
        "\n",
        "\n",
        "https://medium.com/@knowledgrator/extract-any-named-entities-from-pdf-using-custom-spacy-pipeline-9fd0af2c3e13"
      ],
      "metadata": {
        "id": "24ASRErsQGnz"
      }
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "RKG2DxDKPu4c"
      },
      "outputs": [],
      "source": [
        "# !pip install pdfminer.six spacy\n",
        "# !python -m spacy download en_core_web_sm"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from pdfminer.high_level import extract_pages\n",
        "from pdfminer.layout import LTTextContainer\n",
        "from tqdm import tqdm\n",
        "import re"
      ],
      "metadata": {
        "id": "_KadbrG1QBc5"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def process_document(pdf_path, page_ids=None):\n",
        "   extracted_pages = extract_pages(pdf_path, page_numbers=page_ids)\n",
        "\n",
        "\n",
        "   page2content = {}\n",
        "\n",
        "\n",
        "   # Process each extracted page\n",
        "   for extracted_page in tqdm(extracted_pages):\n",
        "       page_id = extracted_page.pageid\n",
        "       content = process_page(extracted_page)\n",
        "       page2content[page_id] = content\n",
        "\n",
        "\n",
        "   return page2content"
      ],
      "metadata": {
        "id": "86TPZvdgQBhe"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def process_page(extracted_page):\n",
        "   content = []\n",
        "\n",
        "\n",
        "   # Get a sorted list of elements based on\n",
        "                # their Y-coordinate in reverse order\n",
        "   elements = [element for element in extracted_page._objs]\n",
        "   elements.sort(key=lambda a: a.y1, reverse=True)\n",
        "\n",
        "\n",
        "   for i, element in enumerate(elements):\n",
        "       # Extract text if the element is a text container\n",
        "       # and text extraction is enabled\n",
        "       if isinstance(element, LTTextContainer):\n",
        "           line_text = extract_text_and_normalize(element)\n",
        "           content.append(line_text)\n",
        "\n",
        "   # Combine and clean up the extracted content\n",
        "   content = re.sub('\\n+', '\\n', ''.join(content))\n",
        "   return content"
      ],
      "metadata": {
        "id": "3y04ujL9QBka"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def extract_text_and_normalize(element):\n",
        "   # Extract text from line and split it with new lines\n",
        "   line_texts = element.get_text().split('\\n')\n",
        "   norm_text = ''\n",
        "   for line_text in line_texts:\n",
        "       line_text=line_text.strip()\n",
        "       # empty strings after striping convert to newline character\n",
        "       if not line_text:\n",
        "           line_text = '\\n'\n",
        "       else:\n",
        "           line_text = re.sub('\\s+', ' ', line_text)\n",
        "           # if the last character is not a letter or number,\n",
        "                                # add newline character to a line\n",
        "           if not re.search('[\\w\\d\\,\\-]', line_text[-1]):\n",
        "               line_text+='\\n'\n",
        "           else:\n",
        "               line_text+=' '\n",
        "       # concatenate into single string\n",
        "       norm_text+=line_text\n",
        "   return norm_text"
      ],
      "metadata": {
        "id": "dGPQGayaQBmy"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!curl \"https://s28.q4cdn.com/781576035/files/doc_financials/2022/ar/PFE-2022-Form-10K-FINAL-(without-Exhibits).pdf\" > pfizer-report.pdf"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nV_oaMuAQBpk",
        "outputId": "17389476-6146-4eb0-c93d-5946753183dc"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
            "                                 Dload  Upload   Total   Spent    Left  Speed\n",
            "100 1565k  100 1565k    0     0  1638k      0 --:--:-- --:--:-- --:--:-- 1637k\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pdf_path = 'pfizer-report.pdf'\n",
        "page2content = process_document(pdf_path, page_ids=[9])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Um_E_wQFQByE",
        "outputId": "514063a5-3320-459a-b36a-76d8086c27d1"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "1it [00:00,  1.66it/s]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import spacy\n",
        "nlp = spacy.load(\"en_core_web_sm\", disable=[\"tok2vec\", \"tagger\", \"parser\", \"attribute_ruler\", \"lemmatizer\"])"
      ],
      "metadata": {
        "id": "A-MJsnR7QB1K"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from spacy import displacy\n",
        "\n",
        "text = page2content[1]\n",
        "doc = nlp(text)\n",
        "displacy.serve(doc, style=\"ent\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "FKfmqnAvRcZ0",
        "outputId": "68170c19-37cf-4bf9-c171-5af146b92c3f"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/spacy/displacy/__init__.py:106: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
            "  warnings.warn(Warnings.W011)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "<span class=\"tex2jax_ignore\"><!DOCTYPE html>\n",
              "<html lang=\"en\">\n",
              "    <head>\n",
              "        <title>displaCy</title>\n",
              "    </head>\n",
              "\n",
              "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
              "<figure style=\"margin-bottom: 6rem\">\n",
              "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We do not disaggregate total R&amp;D expense by development phase or by therapeutic area since, as described above, we do not manage all of our R&amp;D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&amp;D expense by development phase or by therapeutic area would not necessarily be representative of future spending.<br>For additional information, see the Costs and Expenses—Research and Development Expenses section within \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    MD&amp;A\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " and Note 17.<br>\n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Our R&amp;D Pipeline\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              ". The process of drug and biological product discovery from initiation through development and to potential regulatory approval is lengthy and can take \n",
              "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    more than ten years\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
              "</mark>\n",
              ". As of \n",
              "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    January 31, 2023\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
              "</mark>\n",
              ", we had the following number of projects in various stages of R&amp;D:<br>Development of a single compound is often pursued as part of multiple programs. While our drug candidates may or may not receive regulatory approval, new candidates entering clinical development phases are the foundation for future products. Information concerning several of our drug candidates in development, as well as supplemental filings for existing products, is set forth in the Product Developments section within MD&amp;A.<br>The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. For information on the risks associated with R&amp;D, see the Item 1A. Risk Factors—Research and Development section in this Form 10-K.<br>\n",
              "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    COLLABORATION\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
              "</mark>\n",
              " AND \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    CO-PROMOTION\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " <br>We use collaboration and/or co-promotion arrangements to enhance our development, R&amp;D, sales and distribution of certain biopharmaceutical products, which include, among others, the following:<br>\n",
              "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    • Comirnaty\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
              "</mark>\n",
              " is an mRNA-based coronavirus vaccine to help prevent \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    COVID-19\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              ", which is being jointly developed and commercialized with <br>BioNTech. Pfizer and BioNTech equally share the costs of development for the \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Comirnaty\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " program. \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Comirnaty\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " has been granted an approval or an authorization in many countries around the world in populations varying by country. We also share gross profits equally from commercialization of \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Comirnaty\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " and are working jointly with BioNTech in our respective territories to commercialize the vaccine worldwide (excluding \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    China\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              ", \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Hong Kong\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              ", \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Macau\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              " and \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Taiwan\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              "), subject to regulatory authorizations or approvals market by market. For discussion on \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Comirnaty\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              ", see \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    the Overview of Our Performance, Operating Environment\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              ", Strategy and Outlook—COVID-19 section within MD&amp;A.<br>• Eliquis (\n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    apixaban\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              ") is part of \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    the Novel Oral Anticoagulant\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " market and was jointly developed and commercialized with \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    BMS\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " as an alternative treatment option to warfarin in appropriate patients. We fund \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    between 50% and 60%\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
              "</mark>\n",
              " of all development costs depending on the study, and profits and losses are shared equally except in certain countries where we commercialize \n",
              "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Eliquis\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
              "</mark>\n",
              " and pay a percentage of net sales to \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    BMS\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              ". In certain smaller markets we have full commercialization rights and \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    BMS\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " supplies the product to us at cost plus a percentage of the net sales to end-customers.<br>\n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    • Xtandi\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " (enzalutamide) is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor <br>cells that is being developed and commercialized in collaboration with \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Astellas\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              ". We share equally in the gross profits and losses related to \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    U.S.\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              "<br>net sales and also share equally all \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Xtandi\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " commercialization costs attributable to the \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    U.S.\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              " market, subject to certain exceptions. In addition, we share certain development and other collaboration expenses. For international net sales we receive royalties based on a tiered percentage.<br>\n",
              "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    • Bavencio\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
              "</mark>\n",
              " (avelumab) is a human anti-programmed death ligand-1 (PD-L1) antibody that is being developed and commercialized in <br>collaboration with \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Merck\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " KGaA. We jointly fund the majority of development and commercialization costs and split profits equally related to net sales generated from any products containing avelumab.<br>\n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    • Orgovyx\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " (relugolix) is an oral gonadotropin-releasing hormone (\n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    GnRH\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              ") receptor antagonist for the treatment of adult patients with advanced <br>prostate cancer that is being developed and commercialized with \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Myovant\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              ". The companies are also collaborating on \n",
              "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Myfembree\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
              "</mark>\n",
              " (relugolix \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    40\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
              "</mark>\n",
              " mg, estradiol \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    1.0\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
              "</mark>\n",
              " mg, and norethindrone acetate \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    0.5\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
              "</mark>\n",
              " mg) for heavy menstrual bleeding associated with uterine fibroids in premenopausal women and the management of moderate to severe pain associated with endometriosis in premenopausal women. The companies equally share profits and allowable expenses in the \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    U.S.\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              " for \n",
              "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Orgovyx\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
              "</mark>\n",
              ", and in the \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    U.S.\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              " and \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Canada\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              " for \n",
              "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Myfembree\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
              "</mark>\n",
              ", with Myovant bearing our share of allowable expenses up to a maximum of \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    $50 million\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">MONEY</span>\n",
              "</mark>\n",
              " in \n",
              "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    2022\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
              "</mark>\n",
              ". \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Pfizer\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " does not have rights outside of these markets. Myovant remains responsible for regulatory interactions and drug supply and continues to lead clinical development for the relugolix combination tablet.<br>Revenues associated with these arrangements are included in \n",
              "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Alliance\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
              "</mark>\n",
              " revenues (except in certain markets where we have direct sales and except for the majority of revenues for \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Comirnaty\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              ", which are included as direct product revenues). In addition, we have collaboration arrangements for the development and commercialization of certain pipeline products that are in development stage, including, among others, (i)<br>with BioNTech to develop a modified mRNA-based vaccine for the prevention of varicella zoster (Shingles), and (ii) with \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Valneva\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " to co-develop and commercialize \n",
              "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Valneva’s Lyme\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
              "</mark>\n",
              " disease vaccine candidate, VLA15. For further discussion of collaboration and co-promotion agreements, see \n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    the Item 1A. Risk Factors—Collaborations and Other Relationships\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              " with Third Parties section in this Form 10-K and Notes 2 and \n",
              "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    17\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
              "</mark>\n",
              ".<br>INTERNATIONAL OPERATIONS <br>Our operations are conducted globally, and we supply our medicines and vaccines to over \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    185\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
              "</mark>\n",
              " countries and territories. Emerging markets are an important component of our strategy for global leadership, and our commercial structure recognizes that the demographics and rising economic power of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets. Urbanization and the rise of the middle class in emerging markets provide potential growth opportunities for our products.<br>\n",
              "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Pfizer Inc.\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
              "</mark>\n",
              "<br>\n",
              "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    2022\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
              "</mark>\n",
              " Form \n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    10\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
              "</mark>\n",
              "-K <br>\n",
              "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    5\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
              "</mark>\n",
              " <br></div>\n",
              "</figure>\n",
              "</body>\n",
              "</html></span>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Using the 'ent' visualizer\n",
            "Serving on http://0.0.0.0:5000 ...\n",
            "\n",
            "Shutting down server on port 5000.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Extract IRB number from all PDFs in a folder"
      ],
      "metadata": {
        "id": "PW4KFJeahrxh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# !pip install PyMuPDF\n",
        "\n",
        "\n",
        "import os\n",
        "import spacy\n",
        "import fitz  # PyMuPDF\n",
        "from spacy.matcher import Matcher\n",
        "\n",
        "def extract_text_from_pdf(pdf_path):\n",
        "    \"\"\"Extract text from a single PDF file.\"\"\"\n",
        "    text = \"\"\n",
        "    with fitz.open(pdf_path) as doc:\n",
        "        for page in doc:\n",
        "            text += page.get_text()\n",
        "    return text\n",
        "\n",
        "def extract_irb_numbers(text, nlp):\n",
        "    \"\"\"Extract IRB numbers from the given text using spaCy.\"\"\"\n",
        "    matcher = Matcher(nlp.vocab)\n",
        "    pattern = [{\"TEXT\": {\"REGEX\": \"([0-9]{2}KHCC[0-9]{2})\"}}]\n",
        "    matcher.add(\"IRB_NUMBER\", [pattern])\n",
        "\n",
        "    doc = nlp(text)\n",
        "    matches = matcher(doc)\n",
        "\n",
        "    irb_numbers = [doc[start:end].text for match_id, start, end in matches]\n",
        "    return irb_numbers\n",
        "\n",
        "def process_pdfs_in_folder(folder_path):\n",
        "    \"\"\"Process all PDF files in the given folder.\"\"\"\n",
        "    nlp = spacy.load(\"en_core_web_sm\")\n",
        "    for filename in os.listdir(folder_path):\n",
        "        if filename.endswith(\".pdf\"):\n",
        "            pdf_path = os.path.join(folder_path, filename)\n",
        "            text = extract_text_from_pdf(pdf_path)\n",
        "            irb_numbers = extract_irb_numbers(text, nlp)\n",
        "            print(f\"IRB Numbers in {filename}: {irb_numbers}\")\n",
        "\n",
        "# Example usage\n",
        "folder_path = \"/content/\"\n",
        "process_pdfs_in_folder(folder_path)\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vgRWs4MvRcT7",
        "outputId": "4134a031-7bb1-492e-8580-a432a749edd5"
      },
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "IRB Numbers in pfizer-report.pdf: []\n",
            "IRB Numbers in sample.pdf: ['18KHCC02']\n"
          ]
        }
      ]
    }
  ]
}